| abstract |
REFERS TO COMPOUNDS DERIVED FROM ARYL DIHYDROPYRIDINONE AND PIPERIDINONE FROM FORMULA (I) WHERE x E y ARE A SINGLE OR DOUBLE LINK; R1 IS -CONH (C4-C8 ALKYL), -CONHCH2CO-ALKYL (C2-C8), AMONG OTHERS; R2 IS ALKYL (C1-C4), CYCLOALKYL (C3-C4) OR HALOALKYL (C1-C4); R3 IS H, F, Cl, CN, AMONG OTHERS; R4 AND R5 ARE EACH H, F, Cl, OR ALKYL (C1-C4); R6 IS H, HALO, CN, NO2, AMONG OTHERS; R11, R12, R13, R14 AND R15 ARE EACH H, HALO, ALCOXY (C1-C4), HALOALKYL (C1-C4), AMONG OTHERS; R16 IS H O ALKYL (C1-C4). THE PREFERRED COMPOUNDS ARE: (S) -3- (1H-TETRAZOL-5-IL) -4- (p-TOLIL) -6- (4- (4,4,4-TRIFLUOROBUTOXY) PHENYL) -6- (TRIFLUOROMETIL) -5,6-DIHYDROPYRIDIN-2 (1H) -ONE; (S) -N- (4-METOXYPHENYL) -2-OXO-4- (p-TOLIL) -6- (4- (4,4,4-TRIFLUOROBUTOXY) PHENYL) -6- (TRIFLUOROMETHYL) -1,2 , 5,6-TETRAHYDROPYRIDIN-3-CARBOXAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF MONACILGLYCEROL ACILTRANSFERASE (MGAT2) BEING USEFUL IN THE TREATMENT OF DIABETES, INSULIN RESISTANCE, NEPHROPATIA |